NESS ZIONA, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will report its second quarter 2025 financial results and program updates before the open of the U.S. financial markets on Wednesday, August 13, 2025. The Company will host a conference call and a live audio webcast at 8 a.m. ET, to discuss the second ...

Core Viewpoint - BiomX Inc. is set to host a conference call on May 15, 2025, to discuss its first quarter 2025 financial results and provide updates on its business and programs [1]. Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies aimed at targeting and eliminating specific pathogenic bacteria [3]. - The company utilizes its proprietary BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against validated bacterial targets [3].